Skip to main content

Month: May 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project) Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III Results of observational clinical study on Phelan-McDermid syndrome patients published in Frontiers in Psychiatry Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia First patient dosed in NCI-sponsored Phase I/II study of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer First cohort dosed in Phase I/II study of...

Continue reading

Conifex Announces First Quarter 2025 Results

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the first quarter ended March 31, 2025. EBITDA* was $4.9 million for the quarter compared to EBITDA of negative $2.1 million in the fourth quarter of 2024 and negative $0.5 million in the first quarter of 2024. Net income was $0.6 million or $0.02 per share for the quarter versus net loss of $7.8 million or $0.19 per share in the previous quarter and negative $4.5 million or $0.11 per share in the first quarter of 2024. Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. The financial information reflects results of operations from our Mackenzie sawmill and power plant.  Selected Financial Information      (unaudited,...

Continue reading

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. “We’ve followed up on our strong execution in 2024 with excellent progress on all our programs enabled by a strong balance sheet...

Continue reading

TX Rail Products, Inc. Reports Financial Results for Second Quarter of Fiscal 2025

First Half Fiscal 2025 Revenue Growth and Positive Cash from Operations Outpace Prior Year Period ASHLAND, Ky., May 12, 2025 (GLOBE NEWSWIRE) — TX Rail Products, Inc. (OTC Markets PINK: TXRP), a supplier of rail and rail products to the U.S. coal mining industry, short line railroads and tunneling contractors, today announced financial results for the second quarter of fiscal year 2025. Mr. Shrewsbury, CEO and Chairman of TX Rail Products, Inc., commented, “Through the first half of fiscal 2025, we outpaced the same period last year with higher revenue and increased cash from operations. With strong demand signals across our key markets and favorable market conditions for our offerings, we are entering the second half of the year with confidence.” Second Quarter Fiscal Year 2025 Financial Summary Revenue for the second fiscal...

Continue reading

Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance

BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights(All comparisons are year-over-year unless otherwise noted)Revenue increased 8.2% for the first quarterSame-facility revenues increased 5.2% for the first quarter Same-facility cases increased 6.5% for the first quarterNet loss attributable to Surgery Partners, Inc. was $37.7 million for the first quarterAdjusted EBITDA increased 6.6% to $103.9 million for the first quarter2025 GuidanceFull year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to $3.45 billion and $555 million to $565 million,...

Continue reading

Solo Brands, Inc. Announces First Quarter 2025 Results

First Quarter Chubbies Segment Sales up 43.9% and Solo Stove Sales Down, as Expected, to Realign Go-to-Market Strategy; Solid Evidence of Transformation Traction in the Quarter GRAPEVINE, Texas, May 12, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: DTC; OTC: DTCB)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three months ended March 31, 2025. John Larson, Interim President and Chief Executive Officer, commented, “The first quarter’s performance reflected strong sales from the Chubbies segment, up 44% from a year ago, generating segment EBITDA of 26.5% of net sales. We are pleased with Chubbies’ strong consumer engagement and demand. Solo Stove first quarter...

Continue reading

Imperial Reports First Quarter 2025 Financial Results

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the three months ended March 31, 2025. QUARTER HIGHLIGHTS “Imperial delivered solid operating and financial results for the first quarter of 2025”, said Brian Kynoch, President. “Consolidated production totalled 15,842,336 pounds copper and 17,120 ounces gold which was higher by 28% and 33% respectively, compared to the first quarter of 2024. Financially, we achieved strong operating cash flows of $68.3 million along with revenues of $176.6 million and adjusted EBITDA of $97.7 million.” FINANCIAL Total revenue was $176.6 million in the March 2025 quarter compared to $84.6 million in the 2024 comparative quarter. In the March 2025 quarter, Mount Polley mine had 1.9 concentrate shipments...

Continue reading

Inter&Co Inc. Reports Year-Over-Year Net Income Growth of 57%

BELO HORIZONTE, Brazil, May 12, 2025 (GLOBE NEWSWIRE) — Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the leading financial super app providing financial and digital commerce services to 37.7 million customers, today reported financial results for the first quarter of 2025. 1Q25 Highlights:Total clients grew to 37.7 million, with 21.6 million active clients and an activation rate of 57.2%. Net Income of R$287 million, excluding minority interests, up 57% YoY. Return on Equity of 12.9%, up from 9.2% in 1Q24. Efficiency Ratio continued improving and reached 48.8%, 1.3 p.p. better than 4Q24. NPLs over 90 days improved to 4.1%, 0.8 p.p. lower than 1Q24.João Vitor Menin, Global CEO of Inter&Co, commented: “Inter, by design, embodies the transformation of the banking industry. From our focus on innovation and efficient digital...

Continue reading

Farmasiet, Norway’s largest online pharmacy, signs Agillic for advanced customer engagement

Press release – Copenhagen, 12 May 2025 – Agillic A/S  The Norwegian online pharmacy, Farmasiet, signs Agillic for advanced customer engagement to explore untapped business potential. Farmasiet is Norway’s largest online pharmacy, delivering thousands of both prescription drugs, non-prescription drugs and commodities throughout Norway and with pharmacists available online for fast and convenient expert advice. Confident about the business value and potential of more advanced customer engagement, Farmasiet concluded they would need a new platform to deliver on their ambitions. The search was largely influenced by two key criteria: the technology should enable their advanced ideas, and they would need a European solution to ensure full compliance on data privacy and security. Farmasiet decided on Agillic and in just six weeks, they...

Continue reading

Sportradar Reports First Quarter Results

First Quarter 2025 HighlightsRevenue increased 17% to €311 million Profit for the period increased to €24 million and expanded to 7.8% as a percentage of revenue Adjusted EBITDA1 increased 25% to €59 million and Adjusted EBITDA margin1 expanded to 18.9% Net cash generated from operating activities increased 52% to €102 million and Free cash flow1 increased €32 million to €32 million Achieved Customer Net Retention Rate1 of 122% Extended and expanded partnership with Major League Baseball through 2032 Announced agreement to acquire IMG ARENA and its global sports betting rights portfolioST. GALLEN, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.